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Limb-girdle Muscular Dystrophies (LGMD) are heterogeneous inherited muscle disorders 
characterized by progressive weakness and muscle wasting. They show a wide spectrum of 
clinical courses, varying from very mild to severe. It is a genetically heterogeneous group of 
diseases with dominant (LGMD1) and recessive (LGMD2) inheritance. To date, at least 31 loci 
have been identified. The different subtypes can be distinguished by immunohistochemical 
analysis in a muscle biopsy specimen in order to guide and abbreviate the molecular genetic 
investigations. There is a geographical difference in their incidence. 
LGMD2 are prevalent in Arabic countries because of the high rates of consanguinity. Many 
genes were identified in these countries, especially in Maghreb. LGMD type 2C, or δ-
sarcoglycanopathy, is the most frequent in North African populations as a result of the founder 
c.525delT mutation in the Sarcoglycan gene. It was firstly described in Tunisia, in 1977, by Ben 
Hmida in a large consanguineous Tunisian family with Duchenne like phenotype affecting both 
girls and boys. It is characterized by a childhood onset of progressive muscular dystrophy. The 
mean age of onset is between 5 and 6 years, and half of these patients lose ambulation by age 
12 years. Calf hypertrophy and lumbar lordosis are common. Diagnosis confirmation is based on 
muscle biopsy and molecular study. The scarcities of specialized centers and difficulties that can 
prevent patients from benefitting from immunohistochemical analysis complicate their 
diagnosis, management, and genetic counseling. We therefore propose, in our context, that 
screening for c.525delT could be the first test for AR-LGMD, with a good cost/benefit ratio in 
public health strategies, until access to immunohistochemical analysis will be generalized. This 
might be useful not only for management of patients, genetic counseling, and prenatal diagnosis 
in families but also for novel therapeutic approaches and future clinical trials. 
 
